REG - Celadon Pharma. PLC - Interim Report for six months ended 30 June 2022
29/09/2022 07:01
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220929:nRSc0696Ba&default-theme=true
RNS Number : 0696B Celadon Pharmaceuticals PLC 29 September 2022
Celadon Pharmaceuticals Plc (formerly Summerway Capital Plc)
("Celadon", the "Company" or the "Group")
Interim Report for the six months ended 30 June 2022
London, 29 September 2022 - Celadon Pharmaceuticals Plc (AIM: CEL) today
announces its unaudited condensed interim results for the six months ended 30
June 2022.
Strategic and operational highlights for the period and post period end
· Achieved AIM readmission following the reverse takeover of Vertigrow
Technology Ltd
· Successfully completed seventh harvest from Phase 1 grow facility,
with independent third-party testing from the select test batches confirming
high quality, consistent pharmaceutical grade cannabis with high THC profile
· Internal and independent third-party GMP audits completed, and
request issued to MHRA for inspection at earliest possible date, anticipated
to occur in Q4 2022
· Continuation of Phase 2 grow facility build, which remains on track
to become operational in Q1 2023. On completion, the Company believes it
will have the potential to expand its grow capacity to three tonnes per year
· High level of new patient enquiries to LVL clinic generated; feedback
from initial patients reporting improvements in quality of life. Feasibility
study has now formally commenced, enabling the Company to submit the results
to REC before the end of 2022
· Increased shareholding in Kingdom Therapeutics, the early-stage
pharmaceutical company focused on the research and development of the
endocannabinoid system for those with neurological disorders from 17% to 19%
· Post period end, R&D collaboration agreement signed with Phytome
Life Sciences, a leading UK Government licenced cannabinoid R&D company,
to explore the development of novel pharmaceutical medicines, including using
Celadon's API
Financial highlights for the period
· Revenue of £11,258 (June 2021: £nil)
· Operating loss of £1,982,488 (June 2021: £1,032,284)
· Loss before tax of £13,458,323 (June 2021: £1,949,526)
· Cash at 30 June 2022 of £9,075,413 (June 2021: £2,848,289), with
current cash as at 26 September 2022 of £7.3 million
James Short, CEO of Celadon, commented:
"The year to date has seen considerable developments and growth for Celadon.
After the Company's readmission to AIM in March, we have been making progress
on many fronts. As at August 2022, we completed seven harvests of high THC
cannabis from our Phase 1 grow rooms and we have now formally requested that
the MHRA schedule an inspection of the facility. Should the inspection be
successful, we believe we will be one of a limited number of GMP approved
medical cannabis facilities in the world.
"We are pleased with the rate of progress we have achieved in the short time
since listing, including the successful launch of our chronic pain clinic and
the signing of a new R&D collaboration. During the second half of the year
we are determined to continue to advance the business, and we believe that our
patient-centric approach combined with our decision to pursue the regulated,
pharmaceutical route to market will ultimately transform patient outcomes for
the better."
Analyst briefing: 9.00am today
James Short, Chief Executive Officer, will host a virtual presentation
followed by a Q&A session for analysts at 9.00am BST today. Please contact
Powerscourt at celadon@powerscourt-group.com
(mailto:celadon@powerscourt-group.com) / tel: +44 (0) 20 7250 1446 for
details. A copy of the presentation will be published on the Company's website
at www.celadonpharma.co.uk (http://www.celadonpharma.co.uk)
Investor Presentation: 2.30pm today
Management will be hosting a live presentation and Q&A session today at
2.30pm, via the online platform Investor Meet Company. Investors can sign up
to Investor Meet Company for free and attend the presentation via the
following link:
https://www.investormeetcompany.com/celadon-pharmaceuticals-plc/register-investor
(https://www.investormeetcompany.com/celadon-pharmaceuticals-plc/register-investor)
Questions can be submitted pre-event and at any time during the live
presentation via the Investor Meet Company platform.
Enquiries:
Celadon Pharmaceuticals Plc
James Short Via Powerscourt
Arthur Wakeley
Canaccord Genuity Limited (Nominated Adviser and Broker)
Bobbie Hilliam / Andrew Potts / Patrick Dolaghan +44 (0)20 7523 8000
Powerscourt Group
Sarah MacLeod / Nick Johnson / Sam Austrums / +44 (0)20 7250 1446
Ibrahim Khalil celadon@powerscourt-group.com (mailto:celadon@powerscourt-group.com)
About Celadon Pharmaceuticals Plc
Celadon Pharmaceuticals Plc is a UK based pharmaceutical company focused on
the research, cultivation, manufacturing, and sale of breakthrough
cannabis-based medicines. Its primary focus is on improving quality of life
for chronic pain sufferers, as well as exploring the potential of
cannabis-based medicines for other conditions such as autism. Its 100,000 sq.
ft UK facility comprises a laboratory designed to meet GMP standards, and
capacity for a large indoor hydroponic growing facility that has received a
Home Office Licence to legally grow high-THC medicinal cannabis for the
purpose of producing test batches of cannabis oil to support its application
to the MHRA. The Company's subsidiary, LVL, owns a MHRA conditionally-approved
cannabis trial using cannabis based medicinal products to treat chronic pain
in the UK.
For further information please visit our website www.celadonpharma.co.uk
(http://www.celadonpharma.co.uk)
Chief Executive Officer's Statement
Introduction & Overview
I am delighted to present Celadon's interim results for the six months ended
30 June 2022, which has been a period of strong operational and strategic
progress for the Group.
These results, our first as a public company, follow our successful
readmission to AIM in March 2022 as a result of the reverse takeover of
Vertigrow by Summerway Capital Plc (renamed Celadon Pharmaceuticals Plc),
where we raised £8.5 million of equity capital to support our organic growth
plans. On readmission, we became one of a small number of medical cannabis
companies to be admitted to AIM, one of the world's leading growth markets for
small and mid-cap companies.
In a matter of a few short years, cannabis-based medicinal products ("CBMPs")
have expanded rapidly in several international geographies, with a growing
evidence base for their safety and efficacy. In the UK, it is estimated that
there are eight million people with moderate to severely disabling chronic
pain, and around 50 million in the US and approximately 100 million in Europe.
We aim to position Celadon as one of the UK leaders in breakthrough
cannabis-based medicines, and we believe we have the strategy to unlock the
market by building on our early-mover advantage in this highly regulated
sector, as one of only two such companies with the relevant Home Office and
MHRA licences to cultivate and extract high-quality cannabis in the UK for the
purposes of producing test batches of cannabis oil. Our majority owned
subsidiary, LVL Health, is in the advanced stages of the approval process to
be the prospective sponsor of an MHRA and Research Ethics Committee ("REC")
authorised clinical trial for medicinal cannabis for patients suffering
chronic pain in the UK. We believe that once approved by the MHRA and REC,
it will be the only authorised trial investigating the use of medicinal
cannabis for the treatment of chronic pain in the UK at the time it commences.
Celadon's in-house R&D team continues to work on developing advanced
cannabinoid medicines for further clinical trials.
We believe the opportunity for CBMPs in the UK and internationally remains
compelling for the following reasons:
· Large addressable market: there are an estimated eight million people
in the UK with moderate to severely disabling chronic pain, with around 50
million in US and approximately 100 million in Europe. CBMPs are expanding
rapidly internationally across a number of territories including Germany and
Australia
· Growing evidence of efficacy in chronic pain: there is a growing
evidence base for the safety and efficacy of CBMPs, which LVL is experiencing
through the early results from the first patients on LVL's chronic pain study.
The current standard of care - opioids - is estimated to work for only 5-10%
of patients, with widespread evidence noting the harmful side effects of long
term opioid use
To unlock this opportunity, Celadon continues to pursue its strategy, with a
mission and values aligned to deliver this. Critically, our strategy has a
patient-first objective at the heart of everything we do as an organisation.
· Mission: to improve quality of life for patients most in need through
developing breakthrough cannabis-based medicines
· Values: patient-first, collaboration, innovation, determination
Strategy
Celadon's strategy places the Group in a strong position to open up the UK
market, having successfully built a strong foundation over the past three
years, and develop breakthrough cannabis-based medicines for patients. It
builds on the Company's considerable progress to-date, which positions it as
what we believe are one of only two companies to have the Home Office licence
of its kind for producing test batches of cannabis oil, with a cultivation and
Good Manufacturing Practice ("GMP") aligned facility. The regulatory and
capital barriers to entry remain high, and successful MHRA registration and
GMP certification, together with the grant of a further licence from the Home
Office permitting supply for manufacture into finished medicinal products,
would allow Celadon to become one of the first companies in the UK to be able
to sell licensed GMP grade high-THC cannabis-based medicines.
With a strategy based around patient needs and an initial focus on chronic
pain, Celadon has three core pillars to unlock the emerging market
opportunity, which we continue to pursue:
· Grow, extract and sell: create an integrated UK supply chain that is
not reliant on imported, low-quality product; capability to cultivate, extract
to API, distribute flower and cuttings, and sell to the market
· Trial: conduct clinical trials to demonstrate safety and efficacy,
open up the UK market and support the case for NHS reimbursement
· Breakthrough R&D: develop advanced cannabinoid medicines with
novel delivery technologies, led by Celadon's in-house R&D team and
de-risked through industry partnerships
Operational update
Since readmission in March 2022, Celadon has continued to make progress
against its key operational milestones.
Phase 1 cultivation facility
In August 2022, the Company completed its seventh harvest of test batches of
high THC medical cannabis from the Phase 1 grow rooms for the purpose of
supporting its application for MHRA registration as a manufacturer of
medicinal product Active Pharmaceutical Ingredients ("APIs"). The harvested
cannabis flower product has since undergone rigorous internal and independent
testing to assess its consistency, quality and cannabinoid profile. The
results of the independent third-party testing confirmed that the cannabis
flower tested has consistently met Good Agricultural and Collection Practice
("GACP") / pharmaceutical grade standards for medical cannabis, demonstrating
a consistent and high level of THC, well within all testing tolerances.
The harvested high THC cannabis is currently being stored and processed by the
Company for the purposes of its MHRA inspection, which is noted in more detail
below, as part of its GMP certified medical grade cannabis application.
Celadon has been working closely with the Home Office and has been successful
in its application to expand its Home Office licence, which now allows for
increased permitted storage of cannabis products at its Midlands based
facility, and has received the necessary approvals to export its cannabis
products for the purposes of analytical testing.
Phase 2 facility fit out
The Company has made significant progress in the development and fit out of
its second cannabis cultivation space (Phase 2) and processing capacity. It is
on track for its Phase 2 facility to become operational by Q1 2023 and, once
completed, the Company will have the potential to achieve an annualised yield
of approximately three tonnes of high THC pharmaceutical cannabis in the form
of dry flower, with a potential revenue opportunity of £30 million per year.
Although our build and resourcing plans have not been immune to inflationary
cost pressures, we continue to mitigate where possible to ensure the build
programme remains on track, for example, by bringing inhouse the project
management activity and rephasing certain aspects of the build. Since the
beginning of the period the Company has spent approximately £1.4 million on
developing Phase 2 production capacity.
MHRA certification
The Celadon team have worked hard over the period and post period end in
preparing the Company for its MHRA inspection, which is required to receive
MHRA certification. This includes successfully completing internal audits
conducted via third party professional advisers, independent third party
analytical testing of cannabis batches, and initial extractions of flower to
API using Celadon's proprietary high-tech extraction process.
Based on this progress, the Company has requested that MHRA schedule an
inspection at the earliest possible opportunity. The timing for the inspection
will be dependent on resourcing availability at the MHRA, but the Company
anticipates it occurring during Q4 2022.
On the basis of a successful MHRA inspection, and subsequent receipt of MHRA
certification and the grant of a further licence from the Home Office
permitting supply for manufacture into finished pharmaceutical products, the
Directors believe that the Company will become one of the first in the UK to
be licensed to grow and sell high-THC GMP grade API from its own facility, and
one of a limited number of GMP approved medical cannabis facilities in the
world.
LVL's chronic pain trial
LVL, the Company's private pain clinic subsidiary, has conditional approval
from the MHRA for a trial of medical cannabis in patients with non-cancer
chronic pain, allowing the enrolment of up to 5,000 patients. Before the trial
commences, REC requested a feasibility study, designed to demonstrate the
ability to engage and retain patients.
The Company has commenced the enrolment of patients onto the feasibility
study, which has now formally started. In accordance with REC's request, this
will enable the Company to formally submit the results of the study for
approval before the end of 2022. To support the application, the Company has
also requested a pre-submission meeting with REC in Q4 2022.
LVL is continuing to onboard patients into the feasibility study. Enquiries
from patients interested in participating have surpassed the Company's
expectations with over 1,500 potential leads generated. Following some early
delays in patient onboarding (as reported in the June 2022 Business Update),
LVL has continued to work hard to improve its onboarding processes so that the
patient journey becomes more efficient. The Company anticipates seeing the
benefit of this work during Q4 this year.
Initial feedback from patients who have received treatment has been positive,
with improvements in quality of life being reported.
In the period, LVL also received Care Quality Commission approval for its
clinic on Harley Street in London, and the clinic is now able to see patients
in-person.
Breakthrough R&D
Led by Celadon's Chief Scientific Officer and in line with the Company's
strategy, the in-house R&D team has commenced work on exploring
opportunities to broaden the Company's product range of advanced medicines,
using the Company's proprietary cannabinoid API.
To support this goal of developing novel cannabis-based medicines for the
pharmaceutical prescription market, in September, Celadon entered into an
initial partnership agreement to collaborate with Phytome Life Sciences on
early-stage R&D projects. Phytome is a leading UK early-stage
biopharmaceutical company conducting R&D into plant derived therapeutics
with a specific focus on pharmaceutical cannabis, for which it has a UK
Government R&D licence.
The initial partnership agreement will explore the potential to develop novel
medicines for the UK pharmaceutical market. By working with a third-party
R&D specialist partner, Celadon should be able to accelerate and expand
its R&D pipeline with reduced financial and execution risk.
During the period, the Company also increased its stake in Kingdom
Therapeutics, the early-stage pharmaceutical company focused on the research
and development of the endocannabinoid system for those with neurological
disorders, from 17% to 19%.
Commercialisation
Celadon has held a number of positive discussions regarding sales of its
medical cannabis, both in the UK and internationally. For sale as an end
pharmaceutical product, the Company is required to obtain MHRA certification
and a subsequent Home Office licence before it can sell cultivated medical
cannabis commercially.
ESG
As a company, we recognise the importance of operating to the highest
standards of compliance across the business, and we have continued to advance
our approach to ESG, focusing on identifying those issues that are most
material to Celadon's business and its key stakeholders. This work will form
part of a comprehensive ESG strategy.
As a UK pharmaceutical company aiming to develop medicines that might one day
be reimbursed on the UK's National Health Service ("NHS"), Celadon will work
to align with the NHS's requirement that by 2027 suppliers report emissions
and publish a carbon reduction plan aligned with its 2045 net zero targets.
At the heart of Celadon's approach to ESG is that societal benefit will flow
from addressing the UK's 'silent epidemic' of chronic pain (and opioid
misuse), with eight million people experiencing moderate or severely disabling
chronic pain and largely not benefiting from current treatments. This is
Celadon's mission - to improve quality of life for patients most in need
through breakthrough cannabis-based medicines.
Outlook
While the UK market for CBMPs is early in its development, we remain confident
regarding the medium to long term sector outlook and the prospects for Celadon
within this market. We believe that our highly regulated, pharmaceutical
approach is the most effective route to ensuring that patients' needs are met,
and that receipt of the registration to be an MHRA-approved facility and the
grant of a further licence from the Home Office permitting supply for
manufacture into finished medicinal products, together with approval by REC to
commence an MHRA approved trial, will give us a significant early-mover
advantage. Our progress towards these important milestones sets us at the
forefront of this burgeoning market, and in line with the strategy as set out
in the Company's admission document, positions us well for revenue generation
in 2023.
Financial overview
Financial presentation of the Celadon Pharmaceuticals Plc Group results
On 28 March 2022, Summerway Capital Plc ("Summerway") (renamed Celadon
Pharmaceuticals Plc), completed the acquisition of the Vertigrow Technology
Ltd group of companies (Vertigrow) to create the Celadon Pharmaceuticals Plc
group.
The Vertigrow group of companies includes the 100% shareholding in Celadon
Pharma Ltd and the 57.5% shareholding in Harley Street (CPC) Limited.
Prior to the acquisition, Summerway had 8,033,409 ordinary shares in issue,
and was an investing company under the AIM Rules. On acquisition, Summerway
issued 48,848,484 new ordinary shares to the Vertigrow shareholders and to
redeem the Vertigrow convertible loan notes.
Post combination, the Vertigrow shareholders comprised 86% of the Company's
enlarged share capital.
On consolidation and presentation of the Group's financial position,
performance and cash flows, Vertigrow Technology Ltd, was treated as the
accounting acquirer, and the legal parent company Summerway Capital Plc
(renamed Celadon Pharmaceuticals Plc), was treated as the accounting
subsidiary, as if Vertigrow had acquired Summerway and its AIM listing. As a
result, and unlike a traditional acquisition, the value of £80 million
ascribed to Vertigrow will not be capitalised as non-current asset, but
instead recorded in shareholders' equity in the Company's balance sheet.
Instead, the balance sheet at 30 June 2022 shows the acquisition of Summerway
by Vertigrow, which occurred on 28 March 2022. The income statement and
statement of cash flows shows for the six months ended 30 June 2022 are the
results of Vertigrow with the inclusion of Summerway from 28 March 2022. The
balance sheets at 30 June 2021 and 31 December 2021 are also those of
Vertigrow standalone. The income statement and statement of cash flows for
the six months ended 30 June 2021 and the year ended 31 December 2021 are
those of Vertigrow only as well.
In addition, the accounting for the reverse acquisition itself is deemed to be
the issue of shares to the original Summerway Capital Plc shareholders by
Vertigrow Technology Ltd and this is accounted for as a share based payment
which gives rise to a non-cash charge in the income statement of £6.4
million, which is included within the reverse acquisition reserve.
The Reverse Acquisition Accounting is described in more detail in note 5 to
these interim financial statements.
Revenues - in the six months ended 30 June 2022, the Group recorded revenues
from our Harley Street (CPC) Limited clinical study of £11,258 (£nil in the
six months ended 30 June 2021 and £1,500 for the year ended 31 December
2021).
Cost of sales - includes all costs for the Harley Street (CPC) Limited study
patients, including initial suitability tests, medical consultation and
onboarding of all patients.
Gross profit - for the six months ended 30 June 2022, the Company reported a
gross loss of £12,409 versus £nil for the six months ended 30 June 2021 and
a loss of £10,383 for the year ended 31 December 2021. The gross losses
were due to the mix of paying and non-paying patients in these early days of
LVL's feasibility study.
Operating costs - include all people costs, property costs (including
utilities, repairs and maintenance), marketing, and legal and professional
costs. These totalled £1.8 million in the six months ended 30 June 2022
versus £0.9 million (for the six months ended 30 June 2021) and £2.4 million
(year ended 31 December 2021), which comprises all the Vertigrow operating
costs, with Summerway's corporate costs included from 28 March 2022 onwards.
The increase in operating costs reflects the scale up in the Group's people,
operations and cost base pursuant to our enlarged group business plan.
Operating loss - is gross margin less operating costs, depreciation and
amortisation. The operating loss for the six months ended 30 June 2022 was
£2.0 million versus £1.0 million for the six months ended 30 June 2021, and
£2.7 million for the year ended 31 December 2021.
One off and non cash items - in this reporting period there are a number of
non-recurring and non-cash items below Operating Profit, which are detailed as
follows:
Reverse acquisition and listing related costs in the six months ended 30 June
2022:
§ Reverse acquisition share based payment and IPO costs - a £6.4 million
share based payment charge reflecting the net cost of Vertigrow acquiring
Summerway and the AIM listing. This is a non-cash cost. In the six months
ended 30 June 2022 we incurred £1.5 million of advisers costs. (See note
5.)
§ Finance charges on convertible loan notes - in February and March 2021
Vertigrow raised £4.13 million in pre IPO finance via convertible loan notes
(the "CLNs"). These CLNs are categorized at inception between an Embedded
Derivative and a Host Liability, recognising the optionality in the CLN for
the investor to convert their loan note in VTL shares immediately prior to the
acquisition by Summerway. In the six months ended 30 June 2022, the Group
recorded a finance charge of £3.4 million on the convertible loan notes, and
a finance credit of £556,000 on the derivative liability. These are non-cash
items as the loan notes converted into equity on 28 March 2022. (See note
14.)
Both of these costs are non-recurring.
Contingent consideration relating to our investment in Harley Street (CPC) Ltd
- in June 2022 we recognised a finance credit of £375,000 - the release of a
contingent payment relating to our investment in Harley Street (CPC)
Limited. This is a non cash, non-recurring item. (See note 11.)
Finance charge for the Subsidiary Incentive Scheme - Summerway has a share
based long term incentive plan for certain directors, advisors and employees.
In the six months ended 30 June 2022, the Group recognised a £769,000 charge
for this Subsidiary Incentive Scheme. (See note 15.)
Finance charges on our leased assets - Vertigrow has a Right Of Use lease on
its production facility with 22 years remaining. There is also a 3 year
Right Of Use lease on one item of production equipment. The finance charge
on these leased assets of £264,000 is a fair valuation charge to unwind the
respective balance sheet lease liabilities. The charge has increased on the
prior periods as (a) the lease on the production facility was varied in
February 2022; and (b) a 3 year production equipment leased asset was taken on
in the six months ended 30 June 2022. (See note 17.)
Loan interest charges - Vertigrow had three loan funding lines: (a) a UK
Bounce Back loan; (b) a Supplier Loan; and (c) a pre IPO loan from Summerway
Capital Plc. The external loan interest for (b) reduced versus prior period
as the Supplier Loan was repaid in February 2022. The loan interest on (c)
of £53,000 is for the period prior to 28 March 2022, and after that date is
eliminated on consolidation. (See note 13.)
Non Current Assets - in the six months ended 30 June 2022, the Group continued
its capex build, increasing property, plant and equipment by £1.1 million,
and increased the Right of Use asset (and associated lease liability) due to a
lease variation on the business property and entering a new small equipment
lease. (See note 8.)
Current Assets - increased with IPO placing proceeds. Cash balances at 30
June 2022 were £9.1 million.
Current Liabilities - reduced as the £4.13 million convertible loan note
converted to equity on 28 March 2022. The £2.2 million related party loan
between Summerway Capital Plc and Vertigrow Technology Ltd was eliminated on
consolidation from 28 March 2022, and the £375,000 contingent consideration
liability on the purchase of Harley Street (CPC) Limited has been released
(see note 11).
Non-current liabilities - (a) increased as the lease liability increased (by
£1.4 million) due to the property lease variation and a new small equipment
lease; and (b) decreased with the repayment of the supplier loan of £1.5
million (in February 2022).
Net assets - at 30 June 2022 were £10.7 million.
Shareholders' Equity - Share Capital including Share Premium and the Merger
Relief Reserve total £88.3 million at 30 June 2022 following the IPO and
acquisition of Vertigrow Technology Ltd by Summerway Capital Plc; the Reverse
Acquisition Reserve of £59.2 million (which is the consolidation reserve
created on the reverse acquisition of combining Summerway Capital Plc and
Vertigrow Technology Ltd); the Retained losses (increased to £18.2 million)
and the Non-controlling Interest (£468,000) increased with the losses in the
six months ended 30 June 2022.
Cash outflows from operating activities - for the six months ended 30 June
2022 were £3.0 million versus £1.1 million for the six months ended 30 June
2021 and £3.1 million for the year ended 31 December 2021. The main spend
items include people, advisers and utility costs.
Investing activities - in the six months ended 30 June 2022 capex items
totalled £1.2 million. The Group increased its investment in Kingdom
Therapeutics Limited by £18,000 (to £218,000). The Group also received
£3.5 million of cash inflow on the acquisition of Summerway Capital Plc. In
the six months ended 30 June 2021 we spent £304,000 on capex items and
invested £200,000 in Kingdom Therapeutics Limited. In the year ended 31
December 2021 capex items totalled of £542,000, and we invested £500,000
acquiring 57.5% of the issued share capital of Harley Street (CPC) Limited in
addition to our £200,000 investment in Kingdom Therapeutics Limited.
Financing activities - in the six months ended 30 June 2022, the Group raised
£7.5 million of new equity financing (net of allocated issue costs, which
were specifically related to the fundraise process) and repaid a supplier loan
of £1.5 million which was not used. In the six months ended 30 June 2021 the
Group raised £4.1 million of new funding (net of costs) via CLNs, which were
redeemed on 28 March 2022 through the issue of new ordinary shares of
Summerway Capital Plc, as part of the share consideration paid to Vertigrow
Technology Ltd vendors.
Cash balance - at 30 June 2022 the Group had £9.1 million in cash.
CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
For the six-month period ended 30 June 2022
Six months ended Six months ended Year ended
30 June 2022
30 June 2021
31 December 2021
Unaudited Unaudited Unaudited
and restated
Note £ £ £
Revenue 6 11,258 - 1,500
Cost of sales (23,667) - (11,883)
Gross Loss (12,409) - (10,383)
Operating costs (1,799,317) (914,119) (2,383,447)
Depreciation and amortisation 8, 9 (170,762) (118,165) (269,619)
Operating loss (1,982,488) (1,032,284) (2,663,449)
Share-based payment charge as a result of listing 5 (6,399,526) - -
Reverse acquisition costs 5 (1,464,653) (783,297) (777,476)
Long term incentive plan 15 (768,766) - -
Finance charge on leased assets 17 (264,414) (185,792) (383,595)
Finance charge on convertible loan note 14 (3,448,677) (102,182) (191,440)
Finance gain/ charge on derivative liability 14 555,929 154,730 (659,891)
Contingent consideration release 11 374,768 - -
Loan interest 13 (62,988) (808) (70,325)
Finance interest income 2,492 107 191
(11,475,835) (917,242) (2,082,536)
Loss before taxation (13,458,323) (1,949,526) (4,745,985)
Taxation - - -
Loss for the period, being total comprehensive loss for the period (13,458,323) (1,949,526) (4,745,985)
Loss attributable to:
Owners of the Company (13,247,155) (1,949,526) (4,590,707)
Non-controlling interests (211,168) - (155,278)
(13,458,323) (1,949,526) (4,745,985)
Basic and diluted loss per share 7 (25.1p) (4.4p) (10.4p)
CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION
As at 30 June 2022
As at As at As at
30 June 2022
30 June 2021
31 December 2021
Unaudited Unaudited Unaudited
and restated
Note £ £ £
Non-current assets
Intangible assets 10 1,092,136 80,297 1,092,136
Property, plant and equipment 8 2,063,628 883,708 1,020,703
Right of use assets 9 3,247,204 2,335,473 2,285,248
Investments 12 218,000 200,000 200,000
Total non-current assets 6,620,968 3,499,478 4,598,087
Current assets
Inventories 21,187 - 2,494
Trade and other receivables 719,562 98,781 263,518
Cash and cash equivalents 9,075,413 2,848,289 3,823,234
Total current assets 9,816,162 2,947,070 4,089,246
Current liabilities
Trade and other payables (1,188,283) (878,115) (751,294)
Bounce back loan 13 (10,000) (10,000) (10,000)
Convertible loan notes 14 - (4,020,951) (4,924,831)
Lease liabilities 17 (208,112) (150,000) (337,500)
Contingent consideration 11 - - (374,768)
Related party loan 13 - - (2,160,417)
Total current liabilities (1,406,395) (5,059,066) (8,558,810)
Non-current liabilities
Bounce back loan 13 (29,167) (39,167) (34,167)
Lease liabilities 17 (4,341,849) (2,909,609) (2,919,912)
Supplier loan 13 - - (1,533,510)
Total non-current liabilities (4,371,016) (2,948,776) (4,487,589)
Net assets/liabilities 10,659,719 (1,561,294) (4,359,066)
Shareholder's Equity
Share capital 616,697 80,334 80,334
Share premium 22,553,363 7,367,052 7,367,052
Reverse acquisition reserve 5 (59,200,312) (5,935,088) (5,835,088)
Warrant reserve 245,000 - -
Merger relief reserve 65,082,592 - -
Capital redemption reserve 49,500 49,500 49,500
Retained earnings (18,219,361) (3,123,092) (5,764,272)
11,127,479 (1,561,294) (4,102,474)
Non-controlling interest (467,760) - (256,592)
Total Equity 10,659,719 (1,561,294) (4,359,066)
CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY (UNAUDITED AND RESTATED)
For the six months ended 30 June 2022
Share Capital Share premium Merger relief reserve Reverse acquisition reserve Warrant reserve Capital Redemption reserve Retained earnings Equity attributable to owners of the parent Non-controlling interest Total equity
Unaudited Unaudited Unaudited Unaudited Unaudited Unaudited Unaudited Unaudited Unaudited Unaudited
£ £ £ £ £ £ £ £ £ £
Balance at 31 December 2020 61,300 5,711,086 - (4,549,286) - 49,500 (1,173,566) 99,034 - 99,034
Issue of shares in Summerway Capital Plc 19,034 1,655,966 - (1,675,000) - - - - - -
Movement on Reverse Acquisition Reserve - - - 289,198 - - - 289,198 - 289,198
Loss for the period - - - - - - (1,949,526) (1,949,526) - (1,949,526)
Total comprehensive loss for the period - - - - - - (1,949,526) (1,949,526) - (1,949,526)
Balance at 30 June 2021 80,334 7,367,052 - (5,935,088) - 49,500 (3,123,092) (1,561,294) - (1,561,294)
Acquisition of 57.5% of Harley Street (CPC) Limited - - - - - - - - (101,314) (101,314)
Movement on Reverse Acquisition Reserve - - - 100,000 - - - 100,000 - 100,000
Loss for the period - - - - - - (2,641,180) (2,641,180) (155,278) (2,796,458)
Total comprehensive loss for the period - - - - - - (2,641,180) (2,641,180) (155,278) (2,796,458)
Balance at 31 December 2021 80,334 7,367,052 - (5,835,088) - 49,500 (5,764,272) (4,102,474) (256,592) (4,359,066)
Recognition of PLC Net Assets at acquisition date - - - 5,751,004 - - - 5,751,004 - 5,751,004
Issue of shares for acquisition of subsidiary 433,162 - 65,082,592 (65,515,754) - - - - - -
Share-based payment charge - - - 6,399,526 - - 792,066 7,191,592 - 7,191,592
Settlement of convertible loan notes of Vertigrow Technology Ltd 51,686 7,765,893 - - - - - 7,817,579 - 7,817,579
Issue of shares for cash 51,515 8,448,486 - - - - - 8,500,001 - 8,500,001
Cost of share issue - (1,009,180) - - - - - (1,009,180) - (1,009,180)
Warrants issued - (18,888) - - 245,000 - - 226,112 - 226,112
Loss for the period - - - - - - (13,247,155) (13,247,155) (211,168) (13,458,323)
Total comprehensive loss for the period - - - - - - (13,247,155) (13,247,155) (211,168) (13,458,323)
Balance at 30 June 2022 616,697 22,553,363 65,082,592 (59,200,312) 245,000 49,500 (18,219,361) 11,127,479 (467,760) 10,659,719
CONDENSED CONSOLIDATED CASH FLOW STATEMENT
For the six months ended 30 June 2022
Six months ended Six months ended Year ended
30 June 2022
30 June 2021
31 December 2021
Unaudited Unaudited and Restated Unaudited
£ £ £
Cash flows from operating activities
Loss for the period (13,458,323) (1,949,526) (4,745,985)
Adjustments for:
Depreciation and amortisation 170,762 118,165 269,619
Finance charges on leased assets 264,414 185,792 383,595
Finance charge on convertible loan notes 3,448,677 61,897 151,155
Convertible loan transaction costs - 40,285 40,285
Finance charge on derivative liability (555,929) (154,730) 659,891
Finance charge on loans 61,390 106 69,623
Long term incentive plan 768,766 - -
Warrant costs 226,112 - -
Reverse acquisition share-based payment 6,399,526 - -
Contingent consideration release (374,768) - -
Other finance cost (net) (893) 595 511
Operating cash flow before working capital movements (3,050,266) (1,697,416) (3,171,306)
(Increase)/decrease in trade and other receivables (385,469) 329,158 171,718
Increase/(decrease) in trade and other payables 437,970 217,423 (147,781)
(Increase)/decrease in inventories (18,693) 9,790 -
Cash outflow from operating activities (3,016,458) (1,141,045) (3,147,369)
Investing activities
Cash acquired on reverse acquisition 3,494,287 - -
Cash spent on acquisition of Harley Street (CPC) Limited - - (500,000)
Purchase of property, plant and equipment (1,152,589) (303,802) (542,026)
Purchase of investments (18,000) (200,000) (200,000)
Net cash inflow /(outflow) from investing activities 2,323,698 (503,802) (1,242,026)
Financing activities
Interest received (paid) 893 (595) (512)
Proceeds from convertible loan notes (net of costs) - 4,073,500 4,073,500
Supplier loan - interest payment (41,250) - -
Supplier loan - proceeds/(repayment) (1,500,000) - 1,500,000
Bounce Back loan - interest (525) (106) (696)
Bounce Back loan - repayment (5,000) (833) (5,833)
Proceeds on issuing share capital, net of issue costs 7,490,821 289,198 389,198
Intercompany funding prior to reverse acquisition - - 2,125,000
Debt repayment - (167,507) (167,507)
Net cash inflow from financing activities 5,944,939 4,193,657 7,913,150
Net increase in cash and cash equivalents 5,252,179 2,548,810 3,523,755
Cash and cash equivalents at beginning of period 3,823,234 299,479 299,479
Cash and cash equivalents at end of period 9,075,413 2,848,289 3,823,234
NOTES TO THE INTERIM FINANCIAL STATEMENTS
For the six-months ended 30 June 2022
1. About Celadon Pharmaceuticals Plc
Celadon Pharmaceuticals Plc (the "Company"), formerly Summerway Capital Plc,
is a public limited company incorporated in England and Wales and domiciled in
the United Kingdom (company number: 11545912). It is a public company listed
on the AIM market of the London Stock Exchange. The registered address is
32-33 Cowcross Street, London, EC1M 6DF.
In the period up to 28 March 2022, the activity of the Company was the
investment, acquisition and subsequent development of companies where the
Directors believe there were tangible opportunities to drive strategic,
operational and performance improvement, either as a standalone entity or as a
result of broader initiatives.
On 28 March 2022, the Company completed the acquisition of Vertigrow
Technology Ltd (and its subsidiaries Celadon Pharma Ltd and Harley Street
(CPC) Limited) and the settlement of the Vertigrow Technology Ltd convertible
loan notes through the issuing of 48,484,848 new ordinary shares. The Company
also issued 5,151,516 new ordinary shares and raised gross proceeds of £8.5
million before fees.
These condensed consolidated interim financial statements ("interim financial
statements") as at and for the six months ended 30 June 2022 comprise the
Company and its subsidiaries (together referred to as the "Group").
The companies in the Group at 30 June 2022 are:
Entity Shareholding
Celadon Pharmaceuticals Plc
(formerly Summerway Capital Plc)
Summerway Subco Limited 100% subsidiary of Celadon Pharmaceuticals Plc
Vertigrow Technology Ltd 100% subsidiary of Celadon Pharmaceuticals Plc
Celadon Pharma Ltd 100% subsidiary of Vertigrow Technology Ltd
Celadon Pharmaceuticals (UK) Limited 100% subsidiary of Vertigrow Technology Ltd
Harley Street (CPC) Limited 57.5% subsidiary of Vertigrow Technology Ltd
2. Basis of preparation
These interim financial statements and accompanying notes have neither been
audited nor reviewed by the auditor, do not constitute statutory accounts
within the meaning of Section 434 of the Companies Act 2006 and do not include
all the information and disclosures required in annual statutory financial
statements. They should be read in conjunction with the Group's Annual Report
and Accounts for the 16 months ended 31 December 2021 which are available on
the Group's website. Those statutory accounts were approved by the Board of
Directors on 28 April 2022 and have been filed with Companies House. The
report of the auditors in those accounts was unqualified and also did not
contain a statement under section 498(2) or (3) of the Act.
The comparative interim information for the Vertigrow Technologies Ltd group
of companies is available from the Summerway Capital Plc Admission Document
(which is available on the Group's website).
The Group has chosen not to adopt IAS 34 "Interim Financial Statements" in
preparing the interim financial statements.
These interim financial statements were approved by the Board of Directors on
28 September 2022.
3. Accounting policies
The financial statements are presented in Sterling which is the functional
currency of the Group and all values are rounded to the nearest Pound Sterling
(£).
Details of significant accounting policies are set out below.
Reverse Takeover of Summerway Capital Plc and creation of the Celadon Pharmaceuticals Plc group of companies
On 28 March 2022 the Company, then named Summerway Capital Plc, became the
legal parent of Vertigrow Technology Ltd. These interim financial statements
are presented as proforma to present the substance of reverse takeover
transaction.
Summerway Capital Plc was renamed Celadon Pharmaceuticals Plc.
The results for the six months ended, and as at 30 June 2022 are those of
Vertigrow Technology Ltd group from 1 January 2022 to 30 June 2022 with the
inclusion of the Summerway Capital Plc group at the acquisition date of 28
March 2022 through to 30 June 2022.
The comparative results for the six months ended, and as at 30 June 2021 and
also for, and as at 31 December 2021, represent the consolidated position of
the Vertigrow Technology Ltd group of companies prior to the reverse
acquisition.
This transaction is deemed outside the scope of IFRS 3 (Revised 2008) and not
considered a business combination because the directors have made a judgement
that prior to the transaction, that Summerway Capital Plc was not a business
under the definition of IFRS 3 Appendix A and the application guidance in IFRS
3.B7-B12 due to that company being a company that had no processes or
capability for outputs (IFRS 3.B7). On this basis, the Directors have
developed an accounting policy for this transaction, applying the principles
set out in IAS 8.10-12, in that the policy adopted is:
§ relevant to the users of the financial information;
§ more representative of the financial position;
§ performance and cash flows of the Group;
§ reflects the economic substance of the transaction, not merely the legal
form; and
§ free from bias, prudent and complete in all material aspects.
The accounting policy adopted by the Directors applies the principles of IFRS
3 in identifying the accounting acquirer (Vertigrow Technology Ltd) and the
presentation of the consolidated financial statements of the legal acquirer
(Summerway Capital Plc) as a continuation of the accounting acquirer's
financial statements (Vertigrow Technology Ltd).
This policy reflects the commercial substance of this transaction as:
§ the original shareholders of the Vertigrow Technology Ltd are the most
significant shareholders after the business combination and initial public
offering, owning 86 per cent of the issued share capital; and
§ the executive management team of Vertigrow became the executive management
of Summerway Capital Plc.
Accordingly, the following accounting treatment and terminology has been
applied in respect of the reverse acquisition:
§ the assets and liabilities of the legal subsidiary Vertigrow Technology Ltd
group are recognised and measured in the group financial statements at the
pre-combination carrying amounts, without reinstatement to fair value;
§ the retained earnings and other equity balances recognised in the group
financial statements reflect the retained earnings and other equity balances
of the Vertigrow Technology Ltd group immediately before the business
combination; and
§ the results of the period from 1 January 2022 to 28 March 2022 are those of
the Vertigrow Technology Ltd group.
However, in the Group interim financial statements:
§ the equity structure presented, reflects the equity structure of the legal
parent (Summerway Capital Plc), including the equity instruments issued under
the share-for-share exchange to effect the business combination; and
§ the cost of the combination has been determined from the perspective of
Vertigrow Technology Ltd group.
Transaction costs of equity transactions relating to the issue and
re-admission of the Company's shares, are accounted for as a deduction from
equity where they relate to the issue of new shares, and listing costs are
charged to the consolidated statement of comprehensive income. See note 5
for further explanation.
Basis of consolidation
The consolidated financial statements incorporate the financial statements of
the Company and entities controlled by the Company (its subsidiary
undertakings). Where necessary, adjustments are made to the financial
statements of the subsidiaries to bring their accounting policies in line with
those of the Group. All intra-Group transactions, balances, income and
expenses are eliminated on consolidation.
Subsidiaries are entities controlled by the Group. The Group "controls" an
entity when it is exposed to, or has rights to, variable returns from its
involvement with the entity and has the ability to affect those returns
through its power over the entity. The financial statements of subsidiaries
are included in the consolidated financial statements from the date on which
control commences until the date on which control ceases.
Non-controlling interests are measured initially at their proportionate share
of the acquiree's identifiable net assets at the date of acquisition.
Going concern
These condensed consolidated unaudited interim financial statements have been
prepared on a going concern basis, which assumes that the Group will continue
in operational existence for the foreseeable future.
The Group currently consumes cash resources and will continue to do so as it
completes the construction of its growing facilities and until sales revenues
are sufficiently high enough to generate net cash inflows.
In assessing whether the going concern assumption is appropriate, the
Directors have taken into account all relevant information about the current
and future position of the Group and including the current level of
resources.
At 30 June 2022 the Group had £9.1 million of cash and net assets of £10.7
million.
Having prepared budgets and cash flow forecasts covering the going concern
period which have been stress tested, the Directors believe the Group has
sufficient resources to meet its obligations for a period of at least 12
months from the date of approval of these financial statements.
Taking these matters into consideration, the Directors consider that the
continued adoption of the going concern basis is appropriate having prepared
cash flow forecasts for the coming 12 months. The financial statements do not
reflect any adjustments that would be required if they were to be prepared on
a non going concern basis.
Revenue recognition
At this stage of the Group's development, revenues relate solely to the
provision of services and products to patients engaged on the clinical study
with Harley Street (CPC) Limited.
Patients engaged on these trials are required to pay an initial fee on joining
the trial and a monthly fee thereafter in relation to the subsequent provision
of clinical products.
The following process is followed in determining the timing of recognition of
revenue:
a. Identification of a contract with a patient.
b. Identifying the performance obligations in relation to the contract.
c. Determining the transaction price and allocate to the performance
obligations.
d. Recognising revenue as the performance obligations are satisfied.
In relation to the initial fees paid by patients on joining a trial, the
performance obligations are to provide an initial suitability screening test
and to determine if the patient is suitable. Revenue is recognised on
provision of the screening test kit to the patient, with the related costs of
test kits recognised in cost of sales.
In relation to subsequent monthly fees paid by patients on the trial, the
performance obligation is to provide monthly supplies of filled cartridges
containing medicinal cannabis. Revenue is recognised on delivery of these
supplies to the patient. The contracts with patients do not include any fixed
term or locked in periods, so monthly fees are only recognised on receipt of
payment.
Convertible loan notes
Debt and equity instruments are classified as either financial liabilities or
as equity in accordance with the substance of the contractual arrangement.
An equity instrument is any contract that evidences a residual interest in the
assets of an entity after deducting all of its liabilities. Equity
instruments issued by the Group are recognised at the proceeds received, net
of direct issue costs.
The component parts of compound instruments, such as convertible loan notes,
are classified separately as financial liabilities and equity in accordance
with the substance of the contractual arrangement.
If the conversion feature of a convertible loan note does not meet the
definition of an equity instrument, that portion is classified as an embedded
derivative and measured accordingly. The debt component of the instrument is
determined by deducting the fair value of the conversion option at inception
from the fair value of the consideration received for the instrument as a
whole. The debt component amount is recorded as a financial liability on an
amortised cost basis using the effective interest rate method until
extinguished upon conversion or at the instrument's maturity date.
Where debt instruments issued by the Group are repurchased or cancelled, the
financial liability is derecognised at the point at which cash consideration
is settled. Upon derecognition, the difference between the liability's
carrying amount that has been cancelled and the consideration paid is
recognised as a gain or loss in the Income Statement, net of any direct
transaction costs.
Embedded derivatives in financial instruments or other host contracts that are
not financial assets are treated as separate derivatives when their risks and
characteristics are not closely related to those of the host contracts and the
host contract are not measured at FVTPL. Derivatives embedded in financial
instruments that are closely related or other host contracts that are
financial assets are not separated, instead the entire contract is accounted
for either at amortised costs or fair value as appropriate.
Financial instruments
Financial assets and liabilities are recognised in the statement of financial
position when the Group becomes a party to the contractual provisions of the
instrument. The Group's financial instruments comprise cash, trade and other
receivables, trade and other payables, and long term incentive arrangements.
Trade, group and other receivables
For purposes of subsequent measurement, trade and other receivables are
classified as financial assets measured at amortised cost.
These financial assets of the Group are subsequently measured at amortised
cost using the effective interest method. The amortised cost is reduced by
impairment losses. Any interest income, foreign exchange gains and losses and
impairment are recognised in profit or loss. Any gain or loss on derecognition
is recognised in profit or loss.
The Group will write-off financial assets, either in their entirety or a
portion thereof, if there is no reasonable expectation of its recovery. A
write-off constitutes a derecognition of a financial asset.
Cash and cash equivalents
The Group manages short-term liquidity through the holding of cash and highly
liquid interest-bearing deposits. Only deposits that are readily convertible
into cash with maturities of three months or less from inception, with no
penalty of lost interest, are shown as cash and cash equivalents.
Impairment of financial assets
An impairment loss is recognised for the expected credit losses on financial
assets when there is an increased probability that the counterparty will be
unable to settle an instrument's contractual cash flows on the contractual due
dates, a reduction in the amounts expected to be recovered, or both. The
probability of default and expected amounts recoverable are assessed using
reasonable and supportable past and forward-looking information that is
available without undue cost or effort.
Financial liabilities and equity
Financial liabilities are obligations to pay cash or other financial assets
and are recognised when the Group becomes a party to the contractual
provisions of the instrument.
Trade, group and other payables
Trade and other payables are initially measured at fair value, net of direct
transaction costs and subsequently measured at amortised cost.
Equity
An equity instrument is any contract that evidences a residual interest in the
assets of the company after deducting all of its liabilities. Equity
instruments issued by the Company are recorded at fair value on initial
recognition net of transaction costs.
Equity comprises the following:
§ Called up share capital represents the nominal value of the equity shares.
§ Share Premium represents the excess over nominal value of the fair value of
consideration received from the equity shares, net of expenses of the share
issue.
§ Capital Redemption Reserve is a statutory, non-distributable reserve into
which amounts are transferred following the redemption or purchase of a
Company's own shares.
§ Merger Relief Reserve is a statutory, non-distributable reserve arising
when conditions set out in section 612 of the Companies Act occur and relate
to the share-premium from shares issued to acquire Vertigrow Technology Ltd.
§ Retained Deficit represents accumulated net gains and losses from
incorporation recognised in the Statement of Comprehensive Income.
§ Reverse Acquisition Reserve includes the accumulated losses incurred prior
to the reverse acquisition and the share capital and share premium of
Summerway Capital Plc (renamed Celadon Pharmaceuticals Plc) at acquisition;
the value of the shares issued to acquire all of the share capital of
Vertigrow Technology Ltd; the value of share capital and share premium of
Vertigrow Technology Limited at acquisition; as well as the reverse
acquisition share based payment expense.
§ Warrant Reserve represents the fair value of warrants issued as part of an
equity based payment.
§ Non-controlling Interest represents the accumulated net gains and losses of
Harley Street (CPC) Limited attributable to the minority shareholder.
Right of use leases
Right of use assets
The Group recognises right-of-use assets at the commencement date of the lease
(i.e. the date the underlying asset is available for use). Right-of-use
assets are measured at cost, less any accumulated depreciation and impairment
losses, and adjusted for any remeasurement of lease liabilities. The cost of
right-of-use assets includes the amount of lease liabilities recognised,
initial direct costs incurred, and lease payments made at or before the
commencement date less any lease incentives received.
Depreciation of Right Of Use Assets
The right-of-use asset is depreciated on a straight line basis over the
shorter of the lease term and the estimated useful lives of the assets as:
§ Leasehold property - over 25 years
§ Leased plant and equipment - over 3 to 5 years
In addition, the right-of-use asset is periodically reduced by impairment
losses, if any, and adjusted for certain remeasurements of the lease
liability.
Lease liabilities
At the commencement date of the lease, the Group recognises lease liabilities
measured at the present value of lease payments to be made over the lease
term. The lease payments include fixed payments (including in substance fixed
payments) less any lease incentives receivable, variable lease payments that
depend on an index or a rate and amounts expected to be paid under residual
value guarantees.
In calculating the present value of lease payments, the Group uses the
incremental borrowing rate at the lease commencement date. After the
commencement date, the amount of lease liabilities is increased to reflect the
accretion of interest and reduced for the lease payments made. The carrying
amount of lease liabilities is remeasured if there is a modification, a change
in the lease term, a change in the lease payments (e.g. changes to future
payments resulting from a change in an index or rate used to determine such
lease payments) or a change in the assessment of an option to purchase the
underlying asset.
Lease payments are allocated between principal and finance cost. The finance
cost is charged to profit or loss over the lease period.
Short-term leases and leases of low-value assets
The Group has elected not to recognise right-of-use assets and lease
liabilities for leases of low-value assets and short-term leases (of less than
12 months) (including IT equipment). The Group recognises the lease payments
associated with these leases as an expense on a straight-line basis over the
lease term.
Property, plant and equipment
Recognition and measurement
Property, plant and equipment are measured at cost, which includes capitalised
borrowing costs, less accumulated depreciation and any accumulated impairment
losses. If significant parts of an item of property, plant and equipment have
different useful lives, then they are accounted for as separate items (major
components) of property, plant and equipment.
Assets under construction is stated at cost, net of accumulated impairment
losses, if any.
Any gain or loss on disposal of an item of property, plant and equipment is
recognised in profit or loss.
Depreciation
Depreciation is calculated to write off the cost of items of property, plant
and equipment less their estimated residual values using the straight-line
method over their estimated useful lives, and is generally recognised in
profit or loss.
The estimated useful lives of property, plant and equipment for current and
comparative periods are as follows:
§ Leasehold improvements - 10 to 25 years
§ Plant and equipment - 3 to 5 years
§ Office equipment and IT - 3 to 5 years
Goodwill
Goodwill represents the future economic benefits arising from a business
combination that are not individually identified and separately recognised.
Goodwill is carried at cost less accumulated impairment loss.
Cost comprises the fair value of assets given, liabilities assumed, and equity
instruments issued, plus the amount of any non-controlling interests in the
acquiree plus, if the business combination is achieved in stages, the fair
value of the existing equity interest in the acquiree.
Goodwill is capitalised as an intangible asset with any impairment in carrying
value being charged to the consolidated statement of comprehensive income.
Impairment tests on Goodwill are undertaken annually at the financial year
end. Where the carrying value of goodwill exceeds its recoverable amount an
impairment is recognised and shall not be reversed in later periods.
Inventory
Inventories are measured at the lower of cost and net realisable value.
There were no biological asset inventories at 30 June 2022 (30 June 2021:
£nil).
Restatement of convertible loan notes at 30 June 2021
In February and March 2021 Vertigrow Technology Ltd secured £4.13 million of
convertible loan note funding.
Under IFRS this is hybrid financial instrument requiring an estimate in the
fair value of the Embedded Derivative to be made at the inception of the
funding and revalued at each reporting date. Vertigrow Technology Ltd
performed these estimates using an intrinsic value approach. The Group has
revised its valuation methodology using a Black Scholes approach to estimate
the fair value of the financial instrument. This restatement is in respect of
amounts disclosed in the admission document.
Impact on 30 June 2021 interim financial statements:
Restated As Stated Impact
30 June 2021 30 June 2021 30 June 2021
Unaudited Unaudited Unaudited
£ £ £
Balance Sheet
Convertible Loan note (2,176,369) (3,099,190) 922,821
Embedded derivative (1,844,582) (1,857,045) 12,463
Net impact on equity (4,020,951) (4,956,235) 935,284
Income Statement
Loan note interest (102,182) (775,027) 672,845
Finance charge on embedded derivative 154,730 51,209 205,939
Net impact on losses for the period 52,548 (723,818) 878,784
Earnings per share (4.4p) (2.4p) (2.0p)
The restatement had no impact on Non-controlling Interest or on cash flows or
the cash flow statement of the Group.
4. Use of judgements and estimates
In preparing the interim financial statements, management has made judgements
and estimates that affect the application of the Group's accounting policies
and the reported amounts of assets, liabilities, income, expenses,
shareholders' equity and reserves. Actual results may differ from these
estimates. Estimates and underlying assumptions are reviewed on an ongoing
basis. Revisions to estimates are recognised prospectively.
In the process of applying the Group's accounting policies, management has
made the following judgements, which have the most significant effect on the
amounts recognised in the interim financial statements:
Reverse Acquisition Accounting
The Celadon Pharmaceuticals Plc Group of companies was formed by Vertigrow
Technology Limited reverse-acquiring Summerway Capital Plc (a "reverse
takeover") on 28 March 2022. Summerway Capital Plc was then renamed Celadon
Pharmaceuticals Plc. The board used judgment in applying Reverse Acquisition
Accounting principles and used significant estimates and assumptions as to the
share price to value the consideration shares issued by Summerway Capital Plc
to the owners of Vertigrow Technology Ltd. Further details are in note 5.
Subsidiary incentive scheme
The Group established a Subsidiary Incentive Scheme in 2018 (in Sumerway Subco
Limited) in order to incentivise and retain key employees, directors and
advisers to the Group. The fair value of share-based awards is measured
using the Monte Carlo model which inherently makes use of significant
estimates and assumptions including the share price volatility, an estimate of
exercise date and the number of scheme members that will achieve the vesting
conditions. Further details of the scheme are given in note 15.
Convertible loan notes
Vertigrow Technology Ltd raised £4.13 million through an issue of convertible
loan notes in February and March 2021. The convertible loan notes contain an
embedded derivative (the right to convert in to shares) that is fair valued at
inception and at each reporting date. The fair value estimate requires
assumptions on share price volatility, the expected value of the shares and
conversion date. Further details are given in note 14.
Leases and right of use assets
In 2019, Vertigrow Technology Ltd signed a 25 year lease on a 100,000
production and head office facility in the UK. The lease was varied in
February of 2022. The fair value accounting for the lease liability and
associated asset value, at inception and the date of variation requires the
estimation of the effective borrowing rate in the lease. Further details are
in note 17.
Acquisition of 57.5% of Harley Street (CPC) Limited
On 14 July 2021, Vertigrow Technology Ltd acquired a 57.5% shareholding in
Harley Street (CPC) Limited for £2.0 million, of which £500,000 was paid in
cash and £1,500,000 of contingent consideration is to be paid in shares in
December 2022, subject to certain targets being achieved. The fair value
accounting for the contingent consideration require an estimation of the
appropriate discount rate at inception and at reporting dates. The
likelihood of the targets being delivered to trigger the contingent
consideration payment required judgement by management. Further details are
in note 11.
5. Reverse Acquisition of Vertigrow Technology Ltd
On 28 March 2022, Summerway Capital Plc (subsequently renamed Caledon
Pharmaceuticals Plc) acquired through a share for share exchange, the entire
share capital of Vertigrow Technology Ltd and its subsidiary companies Celadon
Pharma Ltd and Harley Street (CPC) Limited (together the "Vertigrow Group"),
whose principal activity is growing highly controlled indoor hydroponic, high
THC cannabis for use within medicinal products used to treat chronic pain.
Although the transaction resulted in the Vertigrow Group becoming a wholly
owned subsidiary group of the Company, the transaction constitutes a reverse
acquisition, as the previous shareholders of Vertigrow Technology Ltd own a
substantial majority of the Ordinary Shares of the Company and the executive
management of Vertigrow Technology Ltd became the executive management of
Summerway Capital Plc (renamed as Celadon Pharmaceuticals Plc).
In substance, the shareholders of Vertigrow Technology Ltd acquired a
controlling interest in Summerway Capital Plc and the transaction has
therefore been accounted for as a reverse acquisition. As the Summerway
Capital Plc's activities prior to the acquisition were purely the maintenance
of the AIM Listing, acquiring Vertigrow Technology Ltd and raising equity
finance to provide the required funding for the operations of the acquisition,
it did not meet the definition of a business in accordance with IFRS 3.
Accordingly, this reverse acquisition does not constitute a business
combination and was accounted for in accordance with IFRS 2 "Share-based
Payments" and associated IFRIC guidance.
Although, the reverse acquisition is not a business combination, the Company
has become a legal parent and is required to apply IFRS 10 and prepare
consolidated financial statements. The Directors have prepared these
financial statements using the reverse acquisition methodology, but rather
than recognising goodwill, the difference between the equity value given up by
the Vertigrow Technology Ltd's shareholders and the share of the fair value of
net assets gained by the Vertigrow Technology Ltd shareholders is charged to
the statement of comprehensive income as a share based payment on reverse
acquisition, and represents in substance the cost of acquiring an AIM listing.
In accordance with reverse acquisition accounting principles, these
consolidated financial statements represent a continuation of the consolidated
statements of Vertigrow Technology Ltd and its subsidiaries and include:
a. the assets and liabilities of Vertigrow Technology Ltd and its
subsidiaries at their pre-acquisition carrying value amounts and the results
for the periods presented; and
b. the assets and liabilities of the Company (and its wholly owned
subsidiary Summerway Subco Limited) as at 28 March 2022 and its results from
the date of the reverse acquisition (28 March 2022) to 30 June 2022.
On 28 March 2022, Summerway Capital Plc (renamed Celadon Pharmaceuticals Plc)
issued 43,316,201 ordinary shares to acquire the entire share capital of
Vertigrow Technology Ltd, and issued 5,168,647 ordinary shares to redeem the
Vertigrow Technology Ltd convertible loan notes. At 28 March 2022, the
average share price of Summerway Capital Plc (renamed Celadon Pharmaceuticals
Plc) for the day was £1.5125p.
On consolidation and presentation of the Group's financial position,
performance and cash flows, Vertigrow Technology Ltd, was treated as the
accounting acquirer, and the legal parent company Summerway Capital Plc
(renamed Celadon Pharmaceuticals Plc), was treated as the accounting acquiree.
The fair value of the shares deemed to have been issued by Vertigrow
Technology Ltd was calculated at £12,150,530 based on an assessment of the
purchase consideration for a 100% holding of Summerway Capital Plc (renamed
Celadon Pharmaceuticals Plc) on 28 March 2022.
The fair value of the net assets of Summerway Capital Plc (renamed Celadon
Pharmaceuticals Plc) at acquisition was as follows:
£
Cash and equivalents 3,494,287
Other assets 2,284,612
Accounts payable and other liabilities (27,895)
Net assets 5,751,004
The difference between the deemed cost £12,150,530 and the fair value of the
net assets assumed per above of £5,751,004 resulted in £6,399,526 being
expensed within "reverse acquisition expenses" in accordance with IFRS 2,
Share Based Payments, reflecting the economic cost to Vertigrow Technology Ltd
shareholders of acquiring a quoted entity.
The professional fees in the period were £2,492,722, of which £1,028,069 was
charged to the share premium account (6 months ended 30 June 2021: £nil), and
£1,464,653 was expensed in the consolidated statement of comprehensive income
(6 months ended 30 June 2021: £783,297; year ended 31 December 2021:
£777,476.)
The Reverse Acquisition Reserve which arose from the reverse takeover is made
up as follows:
Note Reverse Acquisition Reserve
£
Pre-acquisition total retained earnings of Summerway Capital Plc 1 (1,745,882)
Vertigrow Technology Ltd share capital at acquisition 2 1,661,798
Investment in Vertigrow Technology Ltd, net of convertible loan note charge 3 (65,515,754)
Reverse acquisition expense 4 6,399,526
(59,200,312)
1. Recognition of pre-acquisition equity of Summerway Capital Plc
(renamed as Celadon Pharmaceuticals Plc) as at 28 March 2022.
2. Vertigrow Technology Ltd had issued share capital of £1,661,798. As
these financial statements present the capital structure of the legal parent
entity, the equity of Vertigrow Technology Ltd is eliminated.
3. The value of the shares issued by the Company in exchange for the
entire share capital of Vertigrow Technology Ltd.
4. The reverse acquisition expense represents the difference between the
value of the equity issued by the Company, and the deemed consideration given
by Vertigrow Technology Ltd to acquire the Company.
6. Revenue
The Group recorded revenue in the 6 months ended 30 June 2022 of £11,258 (6
months ended 30 June 2021: £nil; year ended 31 December 2021: £1,500) from
patients on the Group's clinical study.
7. Loss per share
Basic earnings per share is calculated by dividing the loss/profit after tax
attributable to the equity holders of the group by the weighted average number
of shares in issue during the year. Diluted earnings per share is calculated
by adjusting the weighted average number of shares outstanding to assume
conversion of all potential dilutive shares.
The calculation of earnings per share is based on the following earnings and
number of shares.
In calculating the weighted average number of ordinary shares outstanding (the
denominator of the earnings per share calculation) during the period in which
the reverse acquisition occurs:
§ The number of ordinary shares outstanding from the beginning of that period
to the acquisition date shall be computed, on the basis of the weighted
average number of ordinary shares of the legal acquiree (accounting acquirer)
outstanding during the period multiplied by the exchange ratio established in
the merger agreement; and
§ The number of ordinary shares outstanding from the acquisition date to the
end of that period shall be the actual number of ordinary shares of the legal
acquirer (the accounting acquiree) outstanding during that period.
The basic earnings per share for each comparative period before the
acquisition date presented in the consolidated financial statements following
a reverse acquisition shall be calculated by dividing:
§ the profit or loss of the legal acquiree attributable to ordinary
shareholders in each of those periods by
§ the legal acquiree's historical weighted average number of ordinary shares
outstanding multiplied by the exchange ratio established in the acquisition
agreement.
6 months ended 30 June 2022 6 months ended 30 June 2021 Year ended 31 December 2021
Unaudited Unaudited and restated Unaudited
£ £ £
Loss attributable to the owners of the Company (13,247,155) (1,949,526) (4,590,707)
Weighted average number of ordinary shares in issue 52,847,890 44,622,611 44,324,386
Basic and diluted loss per share (25.1p) (4.4p) (10.4p)
The weighted average number of ordinary shares for the purpose of calculating
the basic and diluted measures is the same. This is because the outstanding
warrants and other instruments would have the effect of reducing the loss per
ordinary share and therefore would be anti-dilutive under the terms of IAS 33.
8. Tangible fixed assets - property, plant and equipment
Leasehold improvement Plant and machinery Office equipment Assets under construction Total
£ £ £ £ £
Cost
At 31 December 2021 465,284 719,168 65,818 - 1,250,270
Additions - 59,426 13,909 1,079,254 1,152,589
At 30 June 2022 465,284 778,594 79,727 1,079,254 2,402,858
Depreciation
At 31 December 2021 (37,411) (177,082) (15,074) - (229,567)
Charge for period (23,265) (74,598) (11,801) - (109,664)
At 30 June 2022 (60,676) (251,680) (26,875) - (339,231)
Net book value
At 31 December 2021 427,873 542,086 50,744 - 1,020,703
At 30 June 2022 404,608 526,914 52,852 1,079,254 2,063,628
Cost
At 31 December 2020 201,611 506,632 - - 708,243
Additions 121,412 127,116 55,274 - 303,802
At 30 June 2021 323,023 633,748 55,274 - 1,012,045
Depreciation
At 31 December 2020 (5,612) (54,786) - - (60,398)
Charge for period (12,184) (52,217) (3,538) - (67,939)
At 30 June 2021 (17,796) (107,003) (3,538) - (128,337)
Net book value
At 31 December 2020 195,999 451,846 - - 647,845
At 30 June 2021 305,227 526,745 51,736 - 883,708
9. Right of use assets
Right of use Right of use
Lease Equipment Total
£ £ £
Cost
At 31 December 2021 2,511,262 - 2,511,262
Additions - 30,225 30,225
Lease variation (1) 766,815 - 766,815
At 30 June 2022 3,278,077 30,225 3,308,302
Amortisation charge
At 31 December 2021 (226,014) - (226,014)
Amortisation charge (before variation) (8,371) - (8,371)
Lease variation - interest reset 234,384 - 234,384
Amortisation charge (after variation) (60,259) (839) (61,098)
At 30 June 2022 (60,259) (839) (61,098)
Net book value
At 31 December 2021 2,285,248 - 2,285,248
At 30 June 2022 3,217,818 29,386 3,247,204
Cost
At 31 December 2020 2,511,261 - 2,511,261
At 30 June 2021 2,511,261 - 2,511,261
Amortisation charge
At 31 December 2020 (125,563) - (125,563)
Amortisation charge (50,225) - (50,225)
At 30 June 2021 (175,788) - (175,788)
Net book value
At 31 December 2020 2,385,699 - 2,385,699
At 30 June 2021 2,335,473 - 2,335,473
1 - In February 2022, Vertigrow Technology Ltd varied the terms of its long
term property lease by (a) extending the rent free period by 12 months to 11
March 2023; and (b) increasing the un-discounted cash flow payments over the
existing lease term (to 30 September 2044) by £3.9 million. On a discounted
cash flow basis this increased the Right Of Use intangible asset and
corresponding Lease Liability by £767k on the variation date.
10. Goodwill
30 June 2022 30 June 2021 31 December 2021
£ £ £
Opening balance 1,092,136 80,297 80,297
Additions in year - - 1,011,839
Ending balance 1,092,136 80,297 1,092,136
On 1 January 2020, Vertigrow Technology Ltd acquired 100% of the share capital
for Celadon Pharma Ltd for £2, together with the assumed liabilities
generated goodwill of £80,297.
On 14 July 2021 Vertigrow Technology Ltd acquired 57.5% of the share capital
of Harley Street (CPC) Limited, together with assumed liabilities generated
goodwill of £1,011,839. (Note 11).
11. Acquisitions - Harley Street (CPC) Limited
On 14 July 2021, Vertigrow acquired 57.5% of the issued share capital of
Harley Street (CPC) Limited ("HSCPCL"), which is in the advanced stages of
obtaining MHRA and Research Ethics Committee approval for a UK-based cannabis
trial for a maximum consideration of £2,000,000.
£500,000 was paid in cash on completion with a contingent consideration
payment of £1,500,000 due in ordinary shares of the Company in the event that
(a) each of MHRA and REC authorise the Trial in full; and (b) 5,000 paying
patients of the Company's clinic are accepted onto the Trial and receive their
first prescriptions under the Trial within 18 months of completion of the
acquisition of LVL.
£
Fair value of initial cash consideration paid 500,000
Fair value of contingent consideration 374,768
Total consideration 874,768
Fair value of net liabilities acquired 238,385
Non-controlling interest (101,314)
Goodwill 1,011,839
The £1,500,000 contingent consideration payment was estimated to have an
acquisition date fair value of £374,768 based upon 6.2% discount rate and
management's probability estimate of the payment criteria being satisfied.
The Directors are in the process of assessing the fair value of net assets
acquired for the 31 December 2022 reporting, and therefore the above figures
are provisional.
At 30 June 2022, the Directors reassessed that the targets for the contingent
consideration payment would not be met within the time frame set, and released
the contingent consideration liability back to consolidated statement of
comprehensive income.
12. Investments
In 2021 Vertigrow Technology Ltd invested £200,000 in Kingdom Therapeutics
Limited (a 17% holding) and acquired an additional holding for £18,000 in May
2022. At 30 June 2022 Vertigrow Technology Limited has a 19% shareholding in
Kingdom Therapeutics Limited.
13. Loans and borrowings
The balance sheet values of our loans and borrowings were:
Related Party Bounce Back Supplier
Loan (1)
Bank Loan (2)
Loan (3)
£ £ £
At 31 December 2020 - (50,000) -
Interest charge - - -
Repayments - 833 -
At 30 June 2021 - (49,167) -
Cash Received (2,125,000) - (1,500,000)
Interest charge (35,417) - (33,510)
Repayments - 5,000 -
At 31 December 2021 (2,160,417) (44,167) (1,533,510)
Interest charge (53,125) - (7,740)
Repayments 5,000 1,541,250
Eliminated on consolidation 2,213,542 - -
At 30 June 2022 - (39,167) -
At 30 June 2022
Due less than 1 year - (10,000) -
Due more than 1 year - (29,167) -
1. Vertigrow Technology Ltd had a £2,125,000 loan from Summerway
Capital Plc (renamed Celadon Pharmaceuticals Plc). Interest accrues at 10%
per annum. This has been eliminated on consolidation on 28 March 2022 in the
reverse takeover.
2. Celadon Pharma Ltd has a 6 year £50,000 Bounce Back Loan with
Barclays Bank Plc with interest fixed at 2.5% pa.
3. Harley Street (CPC) Limited had a £1,500,000 loan from a supplier
with interest at 5% pa. The loan and interest were repaid in full on 4
February 2022.
The amounts charged to the statement of comprehensive income were:
Six months ended Six months ended Year ended
30 June 2022
30 June 2022
31 December 2021
Unaudited Unaudited and restated Unaudited
£ £ £
Related party loan interest (1) 53,125 - 35,417
Supplier loan interest 7,740 - 33,510
Bounce back loan interest 525 106 696
61,390 106 69,623
Other external interest 1,598 702 702
Total Interest charge 62,988 808 70,325
1 - £53,125 of loan interest was incurred by Vertigrow Technology Ltd on
its loan from Summerway Capital Plc in the period from 31 December 2021 up to
28 March 2022. After 28 March 2022 the loan balance and interest have been
eliminated on consolidation.
14. Convertible loan notes - Vertigrow Technology Ltd
In 2021, Vertigrow Technology Ltd issued £4,130,000 convertible loan notes in
February and March 2021, the notes carried interest at 8% pa.
The Company estimated the fair value of the equity component of the
convertible loan notes as embedded derivates totaling £1,997,977 at
inception, and remeasured this fair value at each reporting date, with the
movement recording in the statement of comprehensive income.
The inputs used in the Black Scholes valuation model to calculate those fair
values were:
At Inception 30 June 2021 31 December 2021
Risk free rate -0.03% 0.02% 0.51%
Volatility 54.2% 51.0% 48.0%
Dividend yield 0% 0% 0%
Volatility was estimated using the Summerway Capital Plc share prices for the
periods shown.
The balance sheet values of the host liability and embedded derivative were:
30 June 2022 30 June 2021 31 December 2021
Unaudited Unaudited and restated Unaudited
£ £ £
Amount classified as Host Liability - (2,176,369) (2,265,627)
Amount classified as Embedded Derivative - (1,844,582) (2,659,204)
Net - (4,020,951) (4,924,831)
The amounts charged to the statement of comprehensive income were:
30 June 2022 30 June 2021 31 December 2021
Unaudited Unaudited and restated Unaudited
£ £ £
Finance charge - host liability (43,477) (61,897) (151,155)
Finance charge on redemption of loan notes (3,405,200) - -
(3,448,677) (61,897) (151,155)
Arrangement fees - (40,285) (40,285)
(3,448,677) (102,182) (191,440)
Finance gain on embedded derivative liability 555,929 154,730 (659,891)
Net (2,892,748) 52,548 (851,331)
On 28 March 2022, the convertible loan notes balance of £4,412,379
(comprising: £2,103,274 of derivative liability and £2,309,104 of host
liability and accrued interest) was redeemed through the issuance of 5,168,647
Summerway Capital Plc shares.
15. Subsidiary incentive scheme
On 17 September 2018, the Company established its Subsidiary Incentive Scheme
in order to incentivise and retain certain key employees and directors of, and
advisers to, the Company. On 11 April 2022, the Company amended its
Subsidiary Incentive Scheme in order to cater for the acquisition of Vertigrow
Technology Ltd and a number of directorate and personnel changes to the
Enlarged Group.
Under the terms of the Subsidiary Incentive Scheme, participants are entitled
to subscribe for Subsidiary B Shares. Subsidiary B Shares provide the holder
with a right to participate in any Shareholder value that is created over a
predetermined level and over a three- to five-year period (or upon a change of
control of the Company or the Subsidiary, whichever occurs first). This is
calculated on a formula basis by reference to the growth in market
capitalisation of the Company, following adjustments for the issue of any new
Ordinary Shares and taking into account dividends and capital returns
("Shareholder Value").
On 11 April 2022, the Subsidiary Incentive Scheme was amended to create three
classes of Subsidiary B Shares in issue under the Subsidiary Incentive Scheme:
§ The 400,000 Subsidiary B Shares held by participants under the current
Subsidiary Incentive Scheme (which commenced on 15 January 2021) were
converted into B1 Shares. These B1 Shares will participate in up to 4 per
cent. of Shareholder Value created above a current threshold of £96,305,000
("B1 Initial Value"), being the initial market cap of the Company, plus the
amount of funds raised on 15 January 2021, plus the total subscription value
of the Consideration Shares and the Placing Shares. The B1 Shares will only
participate in that Shareholder Value, however, if the individual elements of
the B1 Initial Value grow at an annual rate of 7.5 per cent. (compounded),
measured over a period of three to five years commencing on 15 January 2021.
§ 650,000 B2 Shares were issued to advisers of Celadon. These B2 Shares will
participate in up to 6.5 per cent. of Shareholder Value created above a
current threshold of £81,755,125 ("B2 Initial Value"), being the
pre-Acquisition value of the Company plus a discounted value of the Celadon
Group (to reflect pre-agreed incentive arrangements and the advisers'
contribute to date) plus the total subscription value of the Placing Shares.
The B2 Shares will only participate in that Shareholder Value, however, if the
individual elements of the B2 Initial Value grow at an annual rate of 17.5 per
cent. (compounded), measured over a period of three to five years commencing
on 28 March 2022.
§ 600,000 B3 Shares were issued to selected management of Celadon. These B3
Shares will participate in up to 6 per cent. of Shareholder Value created
above a current threshold of £101,755,125 ("B3 Initial Value"), being the
pre-Acquisition value of the Company plus the total subscription value of the
Consideration Shares and the Placing Shares. The B3 Shares will only
participate in that Shareholder Value, however, if the individual elements of
the B3 Initial Value grow at an annual rate of 17.5 per cent. (compounded),
measured over a period of three to five years commencing on 28 March 2022.
The current Subsidiary Incentive Scheme participants and their respective
holdings of B Share holdings are noted below.
Name B1 B2 B3 Total
Alexander Anton (Chairman) 75,000 166,666 - 241,666
Benjamin Shaw (former Director) 75,000 166,667 - 241,667
Mark Farmiloe (former Director) 75,000 166,667 - 241,667
Tony Morris (former Director) 125,000 - - 125,000
Paul Gibson (former Director) 50,000 - - 50,000
James Short (Chief Executive Officer) - - 200,000 200,000
Katie Long (Chief Financial Officer) - 150,000 - 150,000
Issued to other employees / consultants - - 400,000 400,000
Total 400,000 650,000 600,000 1,650,000
A summary of the B Shares are as follows:
Tranche B1 B2 B3
Shares in issue 400,000 650,000 600,000
Subscription price 1.4p 1.44p 1.39p
Compound Growth 7.5% pa 17.5% pa 17.5% pa
Exercise period 15 January 2024 to 29 March 2025 to 29 March 2025 to
15 January 2026
29 March 2027
29 March 2027
The B Shares are financial instruments and have been fair valued using a Monte
Carlo simulation with inputs of:
Tranche B1 B2 B3
Risk free rate 1.99% 1.89% 1.89%
Volatility 33.0% 33.0% 33.0%
Dividend yield 0% 0% 0%
Market cap at measurement £58.9 million £58.9 million £58.9 million
Volatility was estimated using the Celadon Pharmaceutical Plc share prices.
Due to the limited share price history of the Company, volatility has been
assessed against an international peer group of comparative entities. An
annualised volatility range of 33% - 127% was developed within the peer group.
Management estimated a volatility of 33%, reflecting the low volatility of the
Celadon Pharmaceuticals Plc share price data post the reverse takeover
transaction.
The Long Term Incentive Plan charge in the income statement for the six months
ended 30 June 2022 was £768,766; and £nil for both the six months ended 30
June 2021 and for the year ended 31 December 2021.
16. Related Party Transactions
Dr. Steve Hajioff
Dr. Steve Hajioff provided consultancy services to Harley Street (CPC) Limited
prior to the Vertigrow's acquisition of its interest in that company.
Vertigrow Technology Ltd entered a consulting agreement with Dr. Steve Hajioff
from 1 June 2021, which terminated on 28 March 2022 when he was appointed to
the Board of Celadon Pharmaceuticals Plc. In the period ended 30 June 2022,
£8,000 of consulting fees were charged to the company (6 months ended 30 June
2021: £2,000; year ended 31 December 2021: £11,000). At 30 June 2022,
£nil was unpaid (30 June 2021: £2,000; at 31 December 2021: £nil).
Kingdom Therapeutics Limited ("Kingdom")
Liz Shanahan is a Director and shareholder of Kingdom, and has been a Director
of Celadon Pharmaceuticals Plc since September 2021.
On 7 June 2021, Vertigrow Technology Ltd subscribed for a 17% shareholding in
Kingdom for £200,000. On 5 May 2022 Vertigrow Technology Ltd purchased an
additional 2.5% shareholding in Kingdom from a selling shareholder for
£18,000.
Related Party Loan (between Summerway Capital Plc and Vertigrow Technology
Ltd)
In October 2021 Summerway Capital Plc provided Vertigrow Technology Ltd with a
secured short term working capital loan with 10% interest pa. At 31 December
2021 and 28 March 2022, £2,125,000 had been drawn down. Interest of
£53,125 was incurred by Vertigrow Technology Ltd in the period from 31
December 2021 up to 28 March 2022. After 28 March 2022 the loan interest and
balance have been eliminated on consolidation.
AFS Advisors LLP
AFS Advisors LLP is an entity indirectly and directly owned by Alexander Anton
(Chairman of the Company) and Benjamin Shaw (a Director of the Company until
28 March 2022).
On 1 February 2021, Vertigrow Technology Ltd entered into an agreement with
AFS Advisors LLP for the provision of strategic and general corporate advice,
including IPO services. Under the terms of the agreement with Vertigrow
Technology Ltd, AFS Advisors LLP were entitled to 5 per cent. of shareholder
value created over certain market capitalisation thresholds. Pursuant to the
agreement, this entitlement was replaced by AFS Advisors LLP's participation
in the Company's Subsidiary Incentive Scheme as described further in note 15.
On 14 January 2022, AFS Advisors LLP and Vertigrow Technology Ltd entered into
an agreement under which AFS Advisors LLP would be entitled to receive an
initial contingent transaction success fee of £350,000 on Admission for
corporate finance and strategic advisory services provided as part of the
transaction. Furthermore, under the terms of the agreement, Vertigrow
Technology Ltd may at its election, award AFS Advisors LLP a discretionary fee
of a further £580,000 within 12 months of Admission, which if paid, would
equate to a total success fee of 1 per cent. of the pre-money value of the
Enlarged Group. In the six months ended 30 June 2022, £350,000 of fees were
charged to the Company (six months ended 30 June 2021: £nil ; year ended 31
December 2021: £nil). At 30 June 2022 £nil was unpaid (30 June 2021:
£nil; at 31 December 2021: £nil).
Tessera Investment Management Limited ("Tessera")
Tony Morris (a former Director of Summerway Capital Plc), and Katie Long (the
Chief Financial Officer of Celadon Pharmaceuticals Plc) are the directors and
shareholders of Tessera.
On 15 January 2021, Summerway Capital Plc entered into an agreement with
Tessera pursuant to which Tessera agreed to provide strategic and general
corporate advice, and M&A and capital raising transaction support
services. Tessera charged £12,500 per month (plus VAT) payable monthly in
arrears from the date of the agreement. The agreement terminated on
readmission of the Group to AIM on 28 March 2022. In the six months ended 30
June 2022, £56,250 of fees were charged to the Company (six months ended 30
June 2021: £62,500; year ended 31 December 2021: £165,000). At 30 June
2022 £nil was unpaid (30 June 2021: £nil; at 31 December 2021: £nil).
On 3 March 2021, Vertigrow Technology Ltd entered into an agreement with
Tessera pursuant to which Tessera has agreed to provide strategic and general
corporate advice, and M&A and capital raising transaction support
services. Under the agreement, Tessera was to participate in the Vertigrow
Technology Ltd share incentive scheme to be implemented in the region of 1.5
per cent. of additional shareholder value created through such scheme, by way
of an allocation to Katie Long on her appointment as CFO. This entitlement was
replaced by Katie Long's participation in the Subsidiary Incentive Scheme
(note 15) at re-admission on comparable terms. In the six months ended 30
June 2022, £54,783 of advisory fees were charged to the Company (six months
ended 30 June 2021: £60,000; year ended 31 December 2021: £150,000). At 30
June 2022 £nil was unpaid (30 June 2021: £nil; at 31 December 2021:
£nil). This agreement was terminated on 28 March 2022.
Subsidiary Incentive Scheme
On the 11 April 2022, and pursuant to the amended Subsidiary Incentive Scheme
detailed in note 15, a number of new B Shares were issued to former and
current Directors of the Company at subscription prices ranging from £0.0139
to £0.0144 per B Share. The current allocation of B shares in issue to
former and current Directors of the Company are set out below.
Name Previous B Shares held Agreed buybacks New B Shares issued pursuant to amended Scheme Current B Shares held
Alexander Anton (Chairman) 75,000 - 166,666 241,666
Benjamin Shaw (former Director) 75,000 - 166,667 241,667
Mark Farmiloe (former Director) 75,000 - 166,667 241,667
Tony Morris (former Director) 175,000 (50,000) - 125,000
Vin Murria (former Director) 1,000,000 (1,000,000) - -
Paul Gibson (former Director) 50,000 - - 50,000
James Short (Chief Executive Officer) - - 200,000 200,000
Katie Long (Chief Financial Officer) - - 150,000 150,000
Issued to other employees / consultants - - 400,000 400,000
Total 1,450,000 (1,050,000) 1,250,000 1,650,000
Shortly after the issuance of the new B Shares detailed above, in accordance
with the terms of the resignation letters of Vin Murria and Tony Morris, all
of Vin Murria's B Shares and 50,000 of Tony Morris' B Shares were bought back
from the Subsidiary on 11 April 2022 at their original subscription cost of
£14,000 and £700 respectively.
Market purchases
On 10 March 2022, Alexander Anton acquired 10,000 ordinary shares of Summerway
Capital Plc as part of a secondary market transaction, which was announced on
10 March 2022. Following this and 209,569 ordinary shares held indirectly as
a result of the share consideration paid by the Summerway Capital Plc to
Vertigrow Technology Ltd's shareholders, Alexander Anton's shareholding in the
Company increased to 1,319,569 ordinary shares, representing 2.1 per cent. Of
the Company's share capital.
17. Lease payments and obligations
The Group has leases for its premises and also for plant and equipment assets,
and has the following undiscounted minimum lease payment commitments under
right of use leases as at 30 June 2022:
Leasehold Property Plant & Equipment Total
£ £ £
Less than 1 year 199,452 8,660 208,112
1 to 2 years 650,000 10,740 660,740
2 to 3 years 650,000 10,740 660,740
3 to 4 years 650,000 5,370 655,370
4 to 5 years 650,000 - 650,000
More than 5 years 11,229,715 - 11,229,715
Total 14,029,167 35,510 14,064,677
The fair value of the lease obligations are:
30 June 2022 30 June 2021 31 December 2021
£ £ £
Leasehold Property
Start of period (3,257,412) (2,873,817) (2,873,817)
Variation (note 9) (1,001,199) - -
Lease payment - - -
Finance charge - lease discount unwind (264,247) (185,792) (383,595)
End of period (4,522,858) (3,059,609) (3,257,412)
Plant & Machinery
Start of period - - -
Inception of lease (30,226) - -
Lease payments 3,290 - -
Finance charge - lease discount unwind (167) - -
End of period (27,103) - -
Total 4,549,961 3,059,609 3,257,412
Due within 12 months 208,112 150,000 337,500
Due after 12 months 4,341,849 2,909,609 2,919,912
18. Commitments and Contingencies
Commitments
At 30 June 2022 the Group had committed capital expenditure amounts of
£150,000 which are expected to be completed by 31 December 2022.
End of lease obligations
Under the Group's right of use property lease, at the end of the lease in (at
the end of 2044), the landlord at their election, may give notice and require
Vertigrow Technology Ltd to restore the leasehold property to its original
condition. The landlord has any not given any restoration notice.
19. Subsequent events
On 28 July 2022, Celadon Pharmaceuticals Plc entered into an agreement with
Tessera for the provision of general corporate and strategic advice to the
Group for a fixed retainer of £5,000 per month, based on a commitment of 4
days per month. Tony Morris (a former Director of Summerway Capital Plc), and
Katie Long (the Chief Financial Officer of Celadon Pharmaceuticals Plc) are
the directors and shareholders of Tessera.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END IR GZGZLNRKGZZMRecent news on Celadon Pharmaceuticals
See all newsREG - Celadon Pharma. PLC - Supply of Products to New US Customer
AnnouncementREG - AIM - AIM Notice - 21/05/2024
AnnouncementREG - Celadon Pharma. PLC - Exercise of Share Options and Total Voting Rights
AnnouncementREG - AIM - AIM Notice - 15/05/2024
AnnouncementREG - Celadon Pharma. PLC - Final Results
Announcement